[{"id":"d62c1b12-231e-41f3-9f47-89579c4ab1f5","acronym":"ACCRU-BR-1701","url":"https://clinicaltrials.gov/study/NCT04197687","created_at":"2021-01-18T20:27:24.447Z","updated_at":"2025-02-25T13:53:04.701Z","phase":"Phase 2","brief_title":"TPIV100 and Sargramostim for the Treatment of HER2 Positive, Stage II-III Breast Cancer in Patients With Residual Disease After Chemotherapy and Surgery","source_id_and_acronym":"NCT04197687 - ACCRU-BR-1701","lead_sponsor":"Academic and Community Cancer Research United","biomarkers":" HER-2 • ER • PGR","pipe":" | ","alterations":" HER-2 positive","tags":["HER-2 • ER • PGR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Herceptin (trastuzumab) • Perjeta (pertuzumab) • Kadcyla (ado-trastuzumab emtansine) • Herzuma (trastuzumab-pkrb) • Ontruzant (trastuzumab-dttb) • Ogivri (trastuzumab-dkst) • Trazimera (trastuzumab-qyyp) • Herwenda (trastuzumab biosimilar) • HER-2/neu peptide vaccine • Leukine (sargramostim) • TPIV100"],"overall_status":"Recruiting","enrollment":" Enrollment 480","initiation":"Initiation: 02/20/2020","start_date":" 02/20/2020","primary_txt":" Primary completion: 01/15/2025","primary_completion_date":" 01/15/2025","study_txt":" Completion: 01/15/2025","study_completion_date":" 01/15/2025","last_update_posted":"2023-12-18"}]